Beth P. Weinman

Jump to:

Beth Weinman is a member of the firm’s life sciences regulatory & compliance practice group. She focuses her practice on FDA regulation and enforcement of laws governing pharmaceuticals, biologics, medical devices, cosmetics and dietary supplements.

As a former lawyer with the U.S. Food and Drug Administration, Beth brings valuable perspective to clients who turn to her for representation in government investigations, assistance with internal compliance investigations, FDA enforcement actions, product recalls and other agency engagement strategies.

Clients frequently look to Beth for representation when facing government investigations or engaging with FDA on regulatory compliance matters, particularly in connection with alleged manufacturing practice violations or inappropriate marketing. She has extensive experience representing clients in False Claims Act (FCA) and Federal Food, Drug, and Cosmetic Act (FDCA) investigations, internal compliance investigations, and other enforcement actions before state and federal regulators. In addition, she regularly counsels clients through product recalls and withdrawals, responses to 483s and warning letters, and matters regarding marketing practices, manufacturing practices, data integrity issues and good clinical practices. Beth also represents clients in administrative litigation.

Prior to joining Ropes & Gray, Beth spent nearly eight years as Associate Chief Counsel for Enforcement within FDA’s Office of Chief Counsel. In that role, she worked closely with FDA’s Office of Criminal Investigations, the U.S. Department of Justice and other government agencies to investigate and, when appropriate, prosecute alleged violations of the FDCA and related crimes (e.g., mail fraud, wire fraud, health care fraud, and conspiracies to defraud) under Title 18. She also worked on numerous parallel and independent FCA investigations involving FDA-regulated drugs and devices, and has significant experience in opioid-related investigations.

Before starting at FDA, Beth spent more than seven years as an associate in the litigation department of a large New York law firm, where she represented several pharmaceutical companies in government investigations and securities class-action lawsuits, among other matters.

Experience

Investigations

Represented global medical device manufacturer in parallel FCA and FDCA investigation into allegations of reporting failures and manufacturing practice violations, leading to DOJ declination.
Represented global medical device manufacturer in parallel FCA and FDCA investigation into manufacturing practice and consumer deception allegations.
Representing an individual and university in connection with a criminal investigation related to research fraud and use of an unapproved device
Representing an individual in an ongoing criminal prosecution alleging conspiracy to defraud FDA in connection with drug manufacturing issues.
Representing an international pharmaceutical distributor in an ongoing criminal investigation into potential violations of the FDCA and state laws governing wholesale distribution of prescription drugs.
Representing individual in FCA investigation related to regulation of HCT/Ps
Led an internal compliance investigation for a U.S. pharmaceutical client in connection with manufacturing and data integrity issues at foreign facility.
Led internal investigation into alleged cGMP and QSR violations in connection with manufacturing of combination product.
Represented a U.S. medical products client in connection with multiple federal parallel criminal and civil investigations involving alleged cGMP and QSR violations .
Prepared client for questioning by FDA in connection with device investigation that lacked an investigational device exemption.
Counseled medical device manufacturer regarding potential civil and criminal exposure associated with cGMP compliance issues at manufacturing site.
Counseled medical device manufacturer regarding potential civil and criminal exposure associated with data integrity issues in preclinical research.

Medical Devices

Representing a global device manufacturer in an assessment of potential enforcement risk associated with device nonconformity, and also advising regarding recall strategy.
Representing medical device manufacturer in internal investigation and strategic engagement with FDA regarding field action.
Counseled medical device manufacturer through recall negotiations with FDA that resulted in a labeling correction rather than a product removal.
Represented and counseled client through self-report of compliance issues impacting multiple product categories and implementation of remediation plan.
Counseled multiple clients through emergency use authorization process for decontamination systems for personal protective equipment and for diagnostic tests in connection with COVID-19 pandemic.
Advised client in connection with device importation.

Pharmaceuticals/Biologics

Advise multiple clients on responses to FDA Form 483 observations
Regularly counsel clients regarding advertising and promotional issues.
Represented pharmaceutical client in connection with challenge to an FDA clinical hold imposed on a Phase II trial.
Advised client in connection with potential regulatory challenge and litigation options in connection with agency denial of certain labeling claims.
Counseled rare disease drug manufacturer in connection with offering compassionate use access to an investigational drug.
Counseled pharmaceutical client in connection with outreach to FDA on question about compliance with unclear regulation.
Counseled client regarding OTC monograph compliance in connection with hand sanitizer.

Other Products

Advised cosmetics company regarding FDA labeling requirements in connection with defense in state and federal consumer class action.
Advised cosmetics company in connection with potential recall scenario
Advised produce company in connection with potential recall scenario.

Credentials

Publications

Co-author, “Preparing for FDA’s Surprise Foreign Drug Inspection Regime,” Law360 (June 28, 2022)
Quoted, “DOJ Enforcement: Talking with US FDA is Not Enough to Get Credit for Self-Disclosure,” Pink Sheet (May 31, 2023)
Co-author, “2022 Enforcement Review for FDA-Regulated Products: Back to Basics,” Ropes & Gray Alert (February 2, 2023)
Co-author, “Potential Upheaval for FDA Regulation of Stem Cell Clinics,” Law360 (January 3, 2023)
Co-author, “How Recalls Really Work,” chapter in “How FDA Really Works: Insights from the Experts” (November 2022)
Quoted, “GMP Violations Won’t Trigger Breach Of DOJ Compliance Agreement, Government Attorneys Say,” Pink Sheet (December 22, 2022)
Quoted, “US DOJ’s Corporate Crime Push Raises Concerns Over Criminalizing FDCA Violations,” Pharma Intelligence (December 13, 2022)
Co-author, “Federal Funding of Medical Countermeasures: Opportunities, Risks, and Enforcement Trends,” Food and Drug Law Institute’s (FDLI) Update (December 5, 2022) (Reprinted with permission of FDLI)
Co-author, “FDA’s Proposed Medical Device Rule is Promising, But Hasty,” Law360 (March 23, 2022)
Co-author, “Expect Aggressive Life Sciences Enforcement In 2022,” Law360 (February 14, 2022)
Co-author, “2021 Enforcement Review: FDA-Regulated Medical Products,” Ropes & Gray Article (January 31, 2022)
Co-author, “What’s Next for COVID-Era Emergency Use Medical Devices,” Law360 (January 19, 2022)
Quoted, “Attorneys Predict Pandemic-Related Rise in False Claims Allegations,” Medtech Insight (December 14, 2021)
Co-author, “The American Medical Product Supply Chain: Will COVID-19 Drive Manufacturing Back Home?” Food and Drug Law Institute’s Food and Drug Law Journal (October 15, 2021) Published with permission of FDLI and the Food and Drug Law Journal
Co-author, “Potential Costs of Reshoring Pharmaceutical Manufacturing,” Bloomberg Law (April 7, 2021)
Co-author, “Review of 2020 FDA Enforcement Activities,” Policy & Medicine (February 15, 2021)
Co-author, “Deconstructing the Consent Decree: A Primer and Recent Trends for FDCA Injunctions,” Food & Drug Law Institute Update Magazine (Winter 2020)
Co-author, “Questions Raised By FDA's New Lab Test Policy,” Law360 (October 20, 2020)
Co-author, “FDA Announces It Will No Longer Review EUA Requests for COVID-19 Laboratory Developed Tests,” Ropes & Gray Alert (October 9, 2020)
Co-author, “District Court Upholds Acclarent Executives Strict Liability Conviction for Off-Label Promotion,” Ropes & Gray Alert (September 17, 2020)
Co-author, “Keeping Track of the Quacks: Drug and Device Enforcement in the COVID-19 Era,” Food and Drug Law Institute Update Magazine (September 2020)
Co-author, “HHS Lab Test Rule's Likely Impact During And After COVID-19,” Law360 (August 31, 2020)
Co-author, “Analysis: FDA Response to COVID-19: A Shifting Landscape,” Ropes & Gray Alert (June 29, 2020)
Co-author, “Pandemic May Spur Reform of Lab Test Regulation,” Law360 (April 7, 2020)
Co-author, “Will the Coronavirus Spur Passage of LDT Reform Legislation,” Ropes & Gray Alert (March 25, 2020)
Co-author, “2019 FDA Enforcement Review: Drugs, Biologics, Devices, and Dietary Supplements,” Ropes & Gray FDA Regulatory Alert (February 4, 2020)
Co-author, “When DOJ Seeks Dismissals Of Life Sciences FCA Cases,” Law360 (December 12, 2019)
Co-author, “Kisor May Be A New Dawn For Challenges To FDA Actions,” Law360 (December 2, 2019)
Co-author, “A Guide To FCA Cooperation Credit For Life Sciences Companies,” Law360 (June 18, 2019)
Co-author, “FDA Draft Guidance On Medical Device Inspections Is Limited,” Law360 (May 10, 2019)
Co-author, “2018 FDA Enforcement Review: Drugs, Biologics And Devices,” Law360 (January 28, 2019)
Profiled, “Fresh From US FDA’s Chief Counsel Office, Beth Weinman Talks Qui Tam and Compliance,” Medtech Insight (November 13, 2018)
Profiled, “Ropes & Gray Adds Ex-FDA Enforcement Pro In DC,” Law360 (October 26, 2018)

Presentations

Moderator, “DOJ Agreements, Dual Reporting and the Role of the Compliance Officer,” 24^th Annual Pharmaceutical and Medical Device Ethics and Compliance Congress (October 26, 2023)
Co-moderator, 9^th Annual International Bar Association World Life Sciences Conference in Washington, D.C. (June 1, 2023)
Presenter, “The Shift Toward U.S. Pharmaceutical Manufacturing: Considerations in Attaining the Right Global Mix,” Fierce Pharma webinar (March 30, 2023)
Presenter, “DOJ, FDA, and Compliance in Criminal Violations of the FDCA (Oh My!),” Food and Drug Law Institute’s Enforcement, Litigation and Compliance Conference Washington, D.C. (December 8, 2022)
Presenter, “New and Emerging Risks for Medical Devices” at the 23^rd Pharmaceutical and Medical Device Ethics and Compliance Congress (October 24, 2022)
Moderator, False Claims Act panel at Food & Drug Law Institute's 2021 Enforcement, Litigation and Compliance Conference (December 10, 2021)
Speaker, “Everything But the FDCA: An Evolving Enforcement Arsenal,” FDLI Annual Conference (May 19, 2021)
Speaker, “Outlook 2021: Washington, D.C. Updates and Insights on Life Sciences and Health Care,” Ropes & Gray Teleconference (February 25, 2021)
Speaker, “Enforcement and Litigation,” FDLI Fundamentals of Vaccine Regulation – Scientific Ingenuity and Rigorous Review (February 4, 2021)
Speaker, “Evolving Off-Label Enforcement Theories,” FDLI Enforcement, Litigation, and Compliance Conference (December 15-16, 2020)
Speaker, “The American Pharmaceutical Supply Chain: Will COVID-19 Drive Manufacturing Back Home?” FDLI 2020 Symposium (November 12-13, 2020)
Moderator, “Continued Reliance on Foreign Drug Manufacturing and the Drug Supply Chain: Manageable Risk or Public Health Concern,” FDLI On-Demand Webinar (September 16, 2020)
Speaker, “What Patient Organizations Should Know to Interact with FDA During COVID-19,” FDLI Conference (September 2, 2020)
Speaker, “COVID-19: Introduction to FDA’s Legal Authorities and Emerging Issues,” FDLI Conference (August 18-19, 2020)
Speaker, “Food and Drug Regulatory Trends and Developments: Navigating Implications for the Year Ahead,” The Knowledge Group Webinar (August 5, 2020)
Moderator, “Enforcement Trends,” FDLI Regenerative Medicine Conference (April 2, 2020)
Speaker, “Violations, Enforcement and International Issues,” FDLI Introduction to Biologics and Biosimilars Law and Regulation (April 1, 2020)
Speaker, “Outlook 2020,” Ropes & Gray Teleconference (January 30, 2020)
Speaker, “Navigating the Intersection Between Litigation Tactics and Regulatory Issues,” FDLI Enforcement, Litigation, and Compliance Conference (December 11-12, 2019)
Speaker, “With Great Influence Comes Great Responsibility,” FDLI 2019 Symposium (November 15, 2019)
Speaker, “Mini Summit XXIII: Social Media Engagement by Manufacturers,” 21^st Annual Pharmaceutical and Medical Device Compliance Congress (November 4-6, 2019)
Presenter, “Violations, Enforcement and International Issues” Food and Drug Law Institute’s Introduction to Biologics and Biosimilars Law and Regulation, Washington, D.C. (October 2, 2019)
Moderator, “Focus on Investigations: Government Trends and Best Practices for Internal Investigations,” FDLI Annual Conference (May 2-3, 2019)
Speaker, “Outlook 2019,” Ropes & Gray Teleconference (January 23, 2019)

Experience

Credentials

Education

Admissions:

Publications

Presentations

Areas of Practice